Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK biotech firm licenses stem cell technology to Merck
SCS believes neural stem cells have potential broad research applications. This includes their use in target identification or validation studies, as well as in small molecule library screening
SCS believes neural stem cells have potential broad research applications. This includes their use in target identification or validation studies, as well as in small molecule library screening
The jury found that Wyeth provided inadequate warnings on its drug Prempro and that the drug caused invasive breast cancer in Jennie Nelson, a 67-year-old Ohio woman. The
The eight-week multi-center, randomized, double-blind, placebo-controlled study enrolled 116 patients with poorly controlled systemic hypertension, approximately half with type 2 diabetes. Patients receiving placebo experienced a 6.4 mm
The report from India’s CNBC-TV 18 channel also said that the auction of Merck’s business was likely to begin next month. Merck announced at the start of the
Shire will pay $64.00 in cash for each share of NRPH common stock, which represents a 14.4 % premium to New River's most recent four-week average closing price
MYC is one of the most frequently deregulated proteins in human cancer, and is associated with many types of aggressive tumors carrying a poor prognosis. “The MYC pathway
“The collaboration with Entelos has generated candidate targets and biomarkers which will be pursued under the extension of our collaboration,” said David Nicholson, executive vice president for R&D
GPCRs are membrane protein receptors that are involved in signal transduction of numerous physiological processes. GPCRs are by far the largest family of known drug targets, and at
Under the current Pharmaceutical Price Regulation Scheme (PPRS) used to set prices, the NHS spends about GBP8 billion a year on branded prescription medicines. The study said that
Both DelSite Biotechnologies and ElSohly Laboratories have cooperative R&D agreements with the National Cancer Institute (NCI). Whereas DelSite’s agreement covers the development of a nasal powder vaccine for